Medical diagnostic device company Welch Allyn has signed an exclusive distribution agreement with LKC Technologies, an inventor of the RETeval DR Visual Electrodiagnostic System.


As part of the deal, Welch Allyn will distribute its branded RETeval DR to healthcare providers outside of the US, which will be used to reduce the risk of sight-threatening disease such as diabetic retinopathy.

RETeval is a handheld electrophysiology based functional screening device that offers a simple and cost-effective way to screen for sight threatening diabetic retinopathy (DR) without leaving the primary care office, according to LKC.

With the device, the health care provider in just a few minutes can screen sight-threatening DR and clinically significant macular edema (CSME).

LKC Technologies president James Datovech said: "We believe that there is an opportunity to make a real impact in the lives of diabetics around the world. LKC is extremely pleased to partner with Welch Allyn."

Welch Allyn plans to start the marketing of RETeval DR in the first quarter of 2015.

RETeval DR and RETeval Complete products are not yet available for clinical use in the US, while RETeval is approved for sale and clinical use in Japan, Australia, Canada, and is CE marked, said LKC.

Image: RETeval DR diabetic retinopathy assessment device. Photo: courtesy of PRNewswire/ LKC Technologies, Inc.